Varda Rotter's Lab - Publications

Prof. Varda Rotter's Lab Publications

1971-1975

1976-1980

1981-1985

1986-1990

1991-1995

1996-2000

2001-2005

2006-2010

2011-2015

1971 - 1975

Pluznik, D.H. and Rotter, V. (1971). Differential response of macrophage precursors and antibody forming cells. In: The Reticuloendothelial system and Immune Phenomena. Plenum Press, N.Y., p. 249.

Pluznik DH, Rotter V, Scheinman R. Kinetics of proliferation of splenic macrophage precursor cells during the early primary immune response. Journal of the Reticuloendothelial Society. 1972 Feb;11(2):154-166.
Globerson A, Rotter V, Nakamura I, Trainin N. Thymus extracts induce differentiation of thymus derived cells. Advances in Experimental Medicine and Biology. 1973;29(0):183-189.
Lonai P, Mogilner B, Rotter V, Trainin N. Studies on the effect of a thymic humoral factor on differentiation of thymus-derived lymphocytes. European Journal of Immunology. 1973 Jan;3(1):21-26.
Rotter V, Globerson A, Nakamura I, Trainin N. Studies on characterization of the lymphoid target cell for activity of a thymus humoral factor. The Journal of Experimental Medicine. 1973 Jul 1;138(1):130-142.
Rotter V, Trainin N. Thymus cell population exerting a regulatory function in the immune response of mice to polyvinyl pyrrolidone. Cell Immunology. 1974 Jul;13(1):76-86.
Trainin N, Levo Y, Rotter V. Resistance to hydrocortisone conferred upon thymocytes by a thymic humoral factor. European Journal of Immunology. 1974 Sep;4(9):634-637.
Rotter V, Trainin N. Proceedings: Increased mitogenic reactivity of lymphoid cells to T lectins induced by thymus humoral factor. Israel Journal of Medical Sciences. 1975 Dec;11(12):1381-1382.

Rotter V, Trainin N. (1975) Inhibition of tumor growth in syngeneic chimeric mice-mediated by a depletion-of suppressor T cells. Transplantation, 20:68-74.

Rotter V, Trainin N. (1975) The thymus and the immune response (In Hebrew) Mada. 19:76-80.

Trainin, N., Small, M., Zipori, D., Umiel, T., Kook, A.I. and Rotter, V. (1975) Characteristics of THF, a thymic hormone In: Biological Properties of Thymic Hormones. (Ed. D.W. van Bekkum) Kooyker Scientific Publications, pp. 117-144.

Levo Y, Rotter V, Ramot B. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease. Biomedicine / [publiee pour l'AAICIG. 1975 Jun 30;23(6):198-200.
Rotter V, Trainin N. Proceedings: Increased mitogenic reactivity of lymphoid cells to T lectins induced by thymus humoral factor. Israel Journal of Medical Sciences. 1975 Dec;11(12):1381-1382.
Rotter V, Trainin N. Inhibition of tumor growth in syngeneic chimeric mice mediated by a depletion of suppressor T cells. Transplantation. 1975 Jul;20(1):68-74.
Rotter V, Trainin N. Elimination of suppressor T-cells in mice undergoing a graft-versus-host reaction expressed by increased response to polyvinylpyrrolidone (PVP). Cell Immunology. 1975 Jul;18(1):199-209.
Rotter V, Trainin N. Increased mitogenic reactivity of normal spleen cells to T lectins induced by thymus humoral factor (THF). Cell Immunology. 1975 Apr;16(2):413-421.

Back to the Top

1976 - 1980

Rotter V, Schlesinger M, Kalderon R, Trainin N. Response of human lymphocytes to PHA and Con A, dependent on and regulated by THF, a thymic hormone. J Immunol. 1976 Nov;117(5 Pt.2):1927-1932.
Rotter V, Trainin N. Depletion of suppressor T cells in syngeneic chimeric mice. Advances in Experimental Medicine and Biology. 1976;66:593-598.
Rotter V, Trainin N. Effect of thymic hormone on the response of different lymphoid cell populations to T mitogens. Israel Journal of Medical Sciences. 1977 Apr;13(4):363-370.
Varsano I, Schonfeld TM, Matoth Y, Shohat B, Englander T, Rotter V, Trainin N. Severe disseminated adenovirus infection successfully treated with a thymic humoral factor, THF. Acta paediatrica Scandinavica. 1977 May;66(3):329-331.
Zaizov R, Vogel R, Cohen I, Varsano I, Shohat B, Rotter V, Trainin N. Thymic hormone (THF) therapy in immunosuppressed children with lymphoproliferative neoplasia and generalized varicella. Biomedicine / [publiee pour l'AAICIG. 1977 Apr;27(3):105-108.
Rotter V, Fink A, Trainin N. In vitro allogeneic response of human lymphocytes dependent upon dialyzable plasma components and a thymic hormone, THF. Cell Immunology. 1978 Mar 15;36(2):242-250.

Trainin, N., Zaizov, R., Yakir, Y. and Rotter, V. (1979). Thymic hormones: Characterization and perspectives. In: The Immune System: Functions and Therapy of Dysfunction. Eds. G. Doria and A. Eshkol. Acad. Press, London 27:159 169.

Rotter V, Trainin N. Role of thymic hormone (THF) and of a thymic plasma recirculating factor (TPRF) in the modulation of human lymphocyte response to PHA and Con A. J Immunol. 1979 Feb;122(2):414-420.
Rotter V, Yakir Y, Trainin N. Role of L-alanine in the response of human lymphocytes to PHA and Con A. J Immunol. 1979 Oct;123(4):1726-1731.
Trainin N, Rotter V, Yakir Y, Leve R, Handzel Z, Shohat B, Zaizov R. Biochemical and biological properties of THF in animal and human models. Annals of the New York Academy of Sciences. 1979;332:9-22.
Zaizov R, Vogel R, Wolach B, Cohen IJ, Varsano I, Shohat B, Handzel Z, Rotter V, Yakir Y, Trainin N. The effect of THF in lymphoproliferative and myeloproliferative diseases in children. Annals of the New York Academy of Sciences. 1979;332:172-183.
Rotter V, Witte ON, Coffman R, Baltimore D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50. Journal of Virology. 1980 Nov;36(2):547-555.
Rager-Zissman, B., Harish, Z., Rotter, V., Yakir, Y. and Trainin, N. (1980). Treatment of mice infected with Sendai virus with THF, a thymic hormone. In: Advances in Allergology and Immunology. A. Oehbling et al., eds. Pergamon Press, Oxford and New York, pp. 25-31.

Back to the Top

1981 - 1985

Rotter V, Boss MA, Baltimore D. Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents. Journal of Virology. 1981 Apr;38(1):336-346.
Rotter V. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proceedings of the National Academy of of the United States of America. 1983 May;80(9):2613-2617.
Rotter V, Abutbul H, Ben-Ze'ev A. P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts. The EMBO Journal. 1983;2(7):1041-1047.
Rotter V, Abutbul H, Wolf D. The presence of p53 transformation-related protein in Ab-MuLV transformed cells is required for their development into lethal tumors in mice. International Journal of Cancer. 1983 Mar 15;31(3):315-320.
Rotter V, Friedman H, Katz A, Zerivitz K, Wolf D. Variation in antigenic determinants of p53 transformation-related protein obtained from various species. J Immunol. 1983 Jul;131(1):329-333.
Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature. 1984 Dec 13-19;312(5995):649-651.
Rotter V, Wolf D, Nicolson GL. The expression of transformation-related protein p53 and p53-containing mRNA in murine RAW117 large cell lymphoma cells of differing metastatic potential. Clinical & Experimental Metastasis. 1984 Jul-Sep;2(3):199-204.
Rotter V, Wolf D, Pravtcheva D, Ruddle FH. Chromosomal assignment of the murine gene encoding the transformation-related protein p53. Molecular and Cellular Biology. 1984 Feb;4(2):383-385.
Wolf D, Admon S, Oren M, Rotter V. Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species. Molecular and Cellular Biology. 1984 Mar;4(3):552-558.
Wolf D, Harris N, Rotter V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell. 1984 Aug;38(1):119-126.
Wolf D, Rotter V. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences. Molecular and Cellular Biology. 1984 Jul;4(7):1402-1410.
Wolf, D. and Rotter, V. (1984). Modification of p53 gene expression by integration of a foreign DNA element. Cold Spring Harbor Conferences on Cell Proliferation and Cancer. The Cancer Cell 2, Oncogenes and Viral Genes, pp. 403 409.

Nicolson, G.L., Rotter, V., Wolf, D., Irimura, T., Reading, C.L., Blick, M., La Biche and Frazier, M. (1985). Biochemistry and Molecular Biology RAW117 large cell lymphoma. In: Biochemistry and Molecular Genetics of Cancer Metastasis, K. Lapis, L.A. Liotta and A.S. Rabson, Eds. Martinus Nijhoff Dr. W. Junk Publishers, Hinghaus, MA.

Rotter V, Wolf D. Biological and molecular analysis of p53 cellular-encoded tumor antigen. Advances in Cancer Research. 1985;43:113-141.
Rotter V, Wolf D, Blick M, Nicolson GL. Expression of abl and other oncogenes is independent of metastatic potential in Abelson virus-transformed malignant murine large cell lymphoma. Clinical & Experimental Metastasis. 1985 Apr-Jun;3(2):77-86.
Wolf D, Harris N, Goldfinger N, Rotter V. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Molecular and Cellular Biology. 1985 Jan;5(1):127-132.
Wolf D, Laver-Rudich Z, Rotter V. In vitro expression of human p53 cDNA clones and characterization of the cloned human p53 gene. Molecular and Cellular Biology. 1985 Aug;5(8):1887-1893.
Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proceedings of the National Academy of Sciences of the United States of America. 1985 Feb;82(3):790-794.

Back to the Top

1986 - 1990

Arai N, Nomura D, Yokota K, Wolf D, Brill E, ShohatO, Rotter V. Immunologically distinct p53 molecules generated by alternative splicing. Molecular and Cellular Biology. 1986 Sep;6(9):3232-3239.
Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V. Molecular basis for heterogeneity of the human p53 protein. Molecular and Cellular Biology. 1986 Dec;6(12):4650-4656.
Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP. Human p53 gene localized to short arm of chromosome 17. Nature. 1986 Feb 27-Mar 5;319(6056):783-784.
Nicolson GL, LaBiche RA, Frazier ML, Blick M, Tressler RJ, Reading CL, Irimura T, Rotter V. Differential expression of metastasis-associated cell surface glycoproteins and mRNA in a murine large cell lymphoma. Journal of Cellular Biochemistry. 1986;31(4):305-312.
Prokocimer M, Shaklai M, Bassat HB, Wolf D, Goldfinger N, Rotter V. Expression of p53 in human leukemia and lymphoma. Blood. 1986 Jul;68(1):113-118.
Shohat O, Greenberg M, Reisman D, Oren M, Rotter V. Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene. 1987;1(3):277-283.
Eliyahu D, Goldfinger N, Pinhasi-Kimhi O, Shaulsky G, Skurnik Y, Arai N, Rotter V, Oren M. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene. 1988 Sep;3(3):313-321.
Pohl J, Goldfinger N, Radler-Pohl A, Rotter V, Schirrmacher V. p53 increases experimental metastatic capacity of murine carcinoma cells. Molecular and Cellular Biology. 1988 May;8(5):2078-2081.
Reisman D, Greenberg M, Rotter V. Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proceedings of the National Academy of Sciences of the United States of America. 1988 Jul;85(14):5146-5150.
Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A, Rotter V. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood. 1989 Nov 15;74(7):2318-2324.
Reisman D, Rotter V. Two promoters that map to 5'-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic cells. Oncogene. 1989 Aug;4(8):945-953.
Reisman D, Rotter V. Induced expression from the Moloney murine leukemia virus long terminal repeat during differentiation of human myeloid cells is mediated through its transcriptional enhancer. Molecular and Cellular Biology. 1989 Aug;9(8):3571-3575.
Reisman, D , and Rotter, V. (1989). Analysis of transcriptional regulatory regions of the human p53 gene in human cells using an EBV-derived shuttle vector. In: Vectors for transfer and expression of genes. NATO ASI Series, Vol H 34, pp419-436. Vectors as Tools for Study of Normal and Abnormal Growth and differentiation. Ed. by H. Lother et al.

Shaulsky G, Ben-Ze'ev A, Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene. 1990 Nov;5(11):1707-1711.
Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Molecular and Cellular Biology. 1990 Dec;10(12):6565-6577.
Trakhtenbrot L, Kelman Z, Rotter V, Haran-Ghera N. Chromosomal mapping of the murine c-abl proto-oncogene by in situ hybridization. Leukemia. 1990 Feb;4(2):136-137.

Back to the Top

1991 - 1995

Foord OS, Bhattacharya P, Reich Z, Rotter V. A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Research. 1991 Oct 11;19(19):5191-5198.
Kern SE, Kinzler KW, Baker SJ, Nigro JM, Rotter V, Levine AJ, Friedman P, Prives C, Vogelstein B. Mutant p53 proteins bind DNA abnormally in vitro. Oncogene. 1991 Jan;6(1):131-136.
Ronen D, Rotter V, Reisman D. Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif. Proceedings of the National Academy of Sciences of the United States of America. 1991 May 15;88(10):4128-4132.
Rotter V, Prokocimer M. p53 and human malignancies. Advances in Cancer Research. 1991;57:257-272.
Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differ. 1991 Dec;2(12):661-667.
Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proceedings of the National Academy of Sciences of the United States of America. 1991 Oct. 15;88(20):8982-8986.
Shaulsky G, Goldfinger N, Rotter V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Research. 1991 Oct 1;51(19):5232-5237.
Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene. 1991 Nov;6(11):2055-2065.
Landesman Y, Pagano M, Draetta G, Rotter V, Fusenig NE, Kimchi A. Modifications of cell cycle controlling nuclear proteins by transforming growth factor beta in the HaCaT keratinocyte cell line. Oncogene. 1992 Aug;7(8):1661-1665.
Ronen D, Teitz Y, Goldfinger N, Rotter V. Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses. Nucleic Acids Research. 1992 Jul 11;20(13):3435-3441.
Almon E, Goldfinger N, Kapon A, Schwartz D, Levine AJ, Rotter V. Testicular tissue-specific expression of the p53 suppressor gene. Developmental Biology. 1993 Mar;156(1):107-116.
Aloni-Grinstein R, Zan-Bar I, Alboum I, Goldfinger N, Rotter V. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene. 1993 Dec;8(12):3297-3305.
Foord O, Navot N, Rotter V. Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein. Molecular and Cellular Biology. 1993 Mar;13(3):1378-1384.
Ragimov N, Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene. 1993 May;8(5):1183-1193.
Reisman D, Elkind NB, Roy B, Beamon J, Rotter V. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ. 1993 Feb;4(2):57-65.
Reisman D, Rotter V. The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Research. 1993 Jan 25;21(2):345-350.
Rotter V, Foord O, Navot N. In search of the functions of normal p53 protein. Trends in Cell Biology. 1993 Feb;3(2):46-49.
Rotter V, Schwartz D, Almon E, Goldfinger N, Kapon A, Meshorer A, Donehower LA, Levine AJ. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proceedings of the National Academy of Sciences of the United States of America. 1993 Oct 1;90(19):9075-9079.
Schwartz D, Goldfinger N, Rotter V. Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene. 1993 Jun;8(6):1487-1494.
Barak Y, Lupo A, Zauberman A, Juven T, Aloni-Grinstein R, Gottlieb E, Rotter V, Oren M. Targets for transcriptional activation by wild-type p53: endogenous retroviral LTR, immunoglobulin-like promoter, and an internal promoter of the mdm2 gene. Cold Spring Harbor Symposia on Quantitative Biology. 1994;59:225-235.
Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood. 1994 Oct 15;84(8):2391-2411.
Rotter V, Aloni-Grinstein R, Schwartz D, Elkind NB, Simons A, Wolkowicz R, Lavigne M, Beserman P, Kapon A, Goldfinger N. Does wild-type p53 play a role in normal cell differentiation? Semin. Cancer Biol. 1994 Jun;5(3):229-236.
Tendler Y, Reshef R, Cohen I, Barzilai M, Shasha SM, Rotter V, Shkolnik T. Histochemical studies of progressive p53 mutations during colonic carcinogenesis in Sprague-Dawley rats induced by N-methyl-N-nitro-nitrosoguanidine or azoxymethane. Pathobiology. 1994;62(5-6):232-237.
Aloni-Grinstein R, Schwartz D, Rotter V. Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. The EMBO Journal. 1995 Apr 3;14(7):1392-1401.
Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M. Direct involvement of p53 in programmed cell death of oligodendrocytes. The EMBO Journal. 1995 Mar 15;14(6):1136-1144.
Elkind NB, Goldfinger N, Rotter V. Spot-1, a novel NLS-binding protein that interacts with p53 through a domain encoded by p(CA)n repeats. Oncogene. 1995 Sep 7;11(5):841-851.
Peller S, Halevy A, Slutzki S, Kopilova Y, Rotter V. p53 mutations in matched primary and metastatic human tumors. Molecular Carcinogenesis. 1995 Jul;13(3):166-172.
Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K, Rotter V. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA and Cell Biology. 1995 Dec;14(12):983-990.
Tendler Y, Schwartz Y, Reshef R, Shasha SM, Rotter V, Shkolnik T. Immunohistochemical detection of p53 protein expression in HPV-induced condyloma acuminatum. Acta dermato-venereologica. 1995 May;75(3):177-179.
Wolkowicz R, Elkind NB, Ronen D, Rotter V. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes. Oncogene. 1995 Mar 16;10(6):1167-1174.
Wolkowicz R, Peled A, Elkind NB, Rotter V. Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. Proceedings of the National Academy of Sciences of the United States of America. 1995 Jul 18;92(15):6842-6846.
Aloni-Grinstein R., Schwatz D., and Rotter V., (1995). p53, A control Protein at the G₂/M Checkpoint. Challenge of Modern Medicine. Differentiation Therapy. (Editor Samuel Waxman) 10, 57-71.

Back to the Top

1996 - 2000

Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M. p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Molecular and Cellular Biology. 1996 Sep;16(9):5178-5185.
Peled A, Schwartz D, Elkind NB, Wolkowicz R, Li R, Rotter V. The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells. Oncogene. 1996 Oct 17;13(8):1677-1685.
Peled A, Zipori D, Rotter V. Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. Cancer Research. 1996 May 1;56(9):2148-2156.
Reisman D, Balint e, Loging WT, Rotter V, Almon E. A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells. Genomics. 1996 Dec 15;38(3):364-370.
Ronen D, Schwartz D, Teitz Y, Goldfinger N, Rotter V. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Differ. 1996 Jan;7(1):21-30.
Schreiber L, Sharabi Y, Schwartz D, Goldfinger N, Brodie C, Rotter V, Shoham J. Induction of apoptosis and p53 expression in immature thymocytes by direct interaction with thymic epithelial cells. Scandinavian Journal of Immunology. 1996 Oct;44(4):314-322.
Almog N, Li R, Peled A, Schwartz D, Wolkowicz R, Goldfinger N, Pei H, Rotter V. The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Molecular and Cellular Biology. 1997 Feb;17(2):713-722.
Almog N, Rotter V. Involvement of p53 in cell differentiation and development. Biochimica et biophysica acta. 1997 Aug 8;1333(1):F1-27.
Rehberger PA, Richter KH, Schwartz D, Goldfinger N, Oskato R, Almog N, Marks F, Rotter V. Differential expression of the regularly spliced wild-type p53 and its COOH-terminal alternatively spliced form during epidermal differentiation. Cell Growth Differ. 1997 Aug;8(8):851-860.
Rotter V, Ronen D. Expression of p53 in differentiation and apoptosis and its deregulation in tumor cell. Leukemia. 1997 Apr;11 Suppl 3:327-330.
Schwartz D, Almog N, Peled A, Goldfinger N, Rotter V. Role of wild type p53 in the G2 phase: regulation of the gamma-irradiation-induced delay and DNA repair. Oncogene. 1997 Nov 20;15(21):2597-2607.
Simons A, Melamed-Bessudo C, Wolkowicz R, Sperling J, Sperling R, Eisenbach L, Rotter V. PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene. 1997 Jan 16;14(2):145-155.
Sthoeger Z, Evron E, Goland S, Shani A, Wolkowicz R, Goldfinger N, Rotter V, Fogel M. Anti-p53 autoantibodies in colon cancer patients. Annals of the New York Academy of Sciences. 1997 Apr 5;815:496-498.
Wolkowicz R, Rotter V. The DNA binding regulatory domain of p53: see the C. Pathologie-biologie. 1997 Dec;45(10):785-796.
Almog N, Rotter V. An insight into the life of p53: a protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998. Biochimica et biophysica acta. 1998 Nov 26;1378(3):R43-54.
Erez-Alon N, Herkel J, Wolkowicz R, Ruiz PJ, Waisman A, Rotter V, Cohen IR. Immunity to p53 induced by an idiotypic network of anti-p53 antibodies: generation of sequence-specific anti-DNA antibodies and protection from tumor metastasis. Cancer Research. 1998 Dec 1;58(23):5447-5452.
Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene. 1998 Jun 25;16(25):3269-3277.
Peller S, Yona R, Kopilova Y, Prokocimer M, Goldfinger N, Uysal A, Karabulut HG, Tukun A, Bokesoy I, Tuncman G, Rotter V. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Genes, Chromosomes & Cancer. 1998 Jan;21(1):2-7.
Prokocimer M, Peller S, Ben-Bassat H, Goldfinger N, Rotter V. P53 gene mutation in a T-acute lymphoblastic leukemia cell line (loucy) with t(16:20) and 5q- chromosomal aberrations. Leukemia & lymphoma. 1998 May;29(5-6):607-611.
Prokocimer M, Unger R, Rennert HS, Rotter V, Rennert G. Pooled analysis of p53 mutations in hematological malignancies. Human Mutation. 1998;12(1):4-18.
Rotter VV. Introduction Semin Cancer Biol. 1998 Oct;8(5):315-316.
Ruiz PJ, Wolkowicz R, Waisman A, Hirschberg DL, Carmi P, Erez N, Garren H, Herkel J, Karpuj M, Steinman L, Rotter V, Cohen IR. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nature Medicine. 1998 Jun;4(6):710-712.
Schwartz D, Rotter V. p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol. 1998;8(5):325-336.
Wolkowicz R, Peled A, Elkind NB, Rotter V. DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus. Cancer Detection and Prevention. 1998;22(1):1-13.
Yaron Y, Schwartz D, Evans MI, Lessing JB, Rotter V. Alternatively spliced mRNA transcripts encoding the extracellular domain of the FSH receptor gene. Expression in the mouse ovary during the ovulatory cycle. The Journal of Reproductive Medicine. 1998 May;43(5):435-438.
Rotter V. (1998). The Role of Wild Type p53 in Tumor Protection and its Loss in Tumor Development and Progression. Seminars in Cancer Biology (Guest Editor). 8, 315-316.

Sigal, A., Matas, D., Almog, N., Li, R., Sutphin, P. D., and Rotter, V. (1999). Interference of mutant p53 with drug induced apoptotic pathways. In: 2nd International Conference on Gastroenterological Carcinogenesis, H. G. Beger and K. H. Link, eds. (Ulm, Germany: Monduzzi Editore), pp. 211-222.

Frenkel J, Sherman D, Fein A, Schwartz D, Almog N, Kapon A, Goldfinger N, Rotter V. Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress. Oncogene. 1999 May 6;18(18):2901-2907.
Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Letters. 1999 May 7;450(3):197-204.
Oren M, Rotter V. Introduction: p53--the first twenty years. Cell Mol Life Sci. 1999 Jan;55(1):9-11.
Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncology Reports. 1999 Jan-Feb;6(1):193-197.
Schwartz D, Goldfinger N, Kam Z, Rotter V. p53 controls low DNA damage-dependent premeiotic checkpoint and facilitates DNA repair during spermatogenesis. Cell Growth Differ. 1999 Oct;10(10):665-675.
Tendler Y, Weisinger G, Coleman R, Diamond E, Lischinsky S, Kerner H, Rotter V, Zinder O. Tissue-specific p53 expression in the nervous system. Brain Research. 1999 Sep 8;72(1):40-46.
Torchinsky A, Ivnitsky I, Savion S, Shepshelovich J, Gorivodsky M, Fein A, Carp H, Schwartz D, Frankel J, Rotter V, Toder V. Cellular events and the pattern of p53 protein expression following cyclophosphamide-initiated cell death in various organs of developing embryo. Teratogenesis, Carcinogenesis, and Mutagenesis. 1999;19(5):353-367.
Uberti D, Schwartz D, Almog N, Goldfinger N, Harmelin A, Memo M, Rotter V. Epithelial cells of different organs exhibit distinct patterns of p53-dependent and p53-independent apoptosis following DNA insult. Experimental Cell Research. 1999 Oct 10;252(1):123-133.
Uberti D, Yavin E, Gil S, Ayasola KR, Goldfinger N, Rotter V. Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin. Brain Research. 1999 Mar 5;65(2):167-175.
Yaron Y, Schwartz D, Evans MI, Aloni R, Kapon A, Rotter V. p53 tumor suppressor gene expression in the mouse ovary during an artificially induced ovulatory cycle. The Journal of Reproductive Medicine. 1999 Feb;44(2):107-114.
Zhao W, He C, Rotter V, Merrick BA, Selkirk JK. An intragenic deletion of nuclear localization signal-1 of p53 tumor suppressor gene results in loss of apoptosis in murine fibroblasts. Cancer Letters. 1999 Dec 1;147(1-2):101-108.
Zhou X, Wang XW, Xu L, Hagiwara K, Nagashima M, Wolkowicz R, Zurer I, Rotter V, Harris CC. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Research. 1999 Feb 15;59(4):843-848.
Almog N, Goldfinger N, Rotter V. p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53. Oncogene. 2000 Jul 13;19(30):3395-3403.
Herkel J, Erez-Alon N, Mimran A, Wolkowicz R, Harmelin A, Ruiz P, Rotter V, Cohen IR. Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA. European Journal of Immunology. 2000 Apr;30(4):977-984.
Homburg S, Visochek L, Moran N, Dantzer F, Priel E, Asculai E, Schwartz D, Rotter V, Dekel N, Cohen-Armon M. A fast signal-induced activation of Poly(ADP-ribose) polymerase: a novel downstream target of phospholipase c. The Journal of Cell Biology. 2000 Jul 24;150(2):293-307.
Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Research. 2000 Dec 15;60(24):6788-6793.
Almog, N., and Rotter, V. (2000). The role of the C'terminus of the p53 tumor suppressor protein. In: Conformational Diseases - A Compendium. Editors: Beka Solomon, Albert Taraboulos, Ephraim Katchalski-Katzir. Publisher: The Center for the Study of Emerging, pages 202-214.

Lilliing G, Hacohen H, Nordenberg J, Livnat T, Rotter V, and Sidi Y, (2000). Differential sensitivity of MCF-7 and LCC2 cells to multiple agents: possible relation to high bcl-2/bax ratio? Cancer Lett. 161, 27-34.

Back to the Top

2001 - 2005

Almog N, Milyavsky M, Stambolsky P, Falcovitz A, Goldfinger N, Rotter V. The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop. Carcinogenesis. 2001 May;22(5):779-785.
Herkel J, Mimran A, Erez N, Kam N, Lohse AW, Marker-Hermann E, Rotter V, Cohen IR. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. Journal of Autoimmunity. 2001 Aug;17(1):63-69.
Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N, Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. The EMBO Journal. 2001 Aug 1;20(15):4163-4172.
Milyavsky M, Mimran A, Senderovich S, Zurer I, Erez N, Shats I, Goldfinger N, Cohen I, Rotter V. Activation of p53 protein by telomeric (TTAGGG)n repeats. Nucleic Acids Research. 2001 Dec 15;29(24):5207-5215.
Offer H, Milyavsky M, Erez N, Matas D, Zurer I, Harris CC, Rotter V. Structural and functional involvement of p53 in BER in vitro and in vivo. Oncogene. 2001 Feb 1;20(5):581-589.
Offer H, Zurer I, Banfalvi G, Reha'k M, Falcovitz A, Milyavsky M, Goldfinger N, Rotter V. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Research. 2001 Jan 1;61(1):88-96.
Seluanov A, Gorbunova V, Falcovitz A, Sigal A, Milyavsky M, Zurer I, Shohat G, Goldfinger N, Rotter V. Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Molecular and Cellular Biology. 2001 Mar;21(5):1552-1564.
Sigal A, Matas D, Almog N, Goldfinger N, Rotter V. The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis. Oncogene. 2001 Aug 9;20(35):4891-4898.
Uberti D, Piccioni L, Cadei M, Grigolato P, Rotter V, Memo M. p53 is dispensable for apoptosis but controls neurogenesis of mouse dentate gyrus cells following gamma-irradiation. Brain Research. 2001 Sep 10;93(1):81-89.
Erez N, Milyavsky M, Goldfinger N, Peles E, Gudkov AV, Rotter V. Falkor, a novel cell growth regulator isolated by a functional genetic screen. Oncogene. 2002 Oct 3;21(44):6713-6721.
Haupt Y, Robles AI, Prives C, Rotter V. Deconstruction of p53 functions and regulation. Oncogene. 2002 Nov 28;21(54):8223-8231.
Herkel J, Modrow JP, Bamberger S, Kanzler S, Rotter V, Cohen IR, Lohse AW. Prevalence of autoantibodies to the p53 protein in autoimmune hepatitis. Autoimmunity. 2002 Dec;35(8):493-496.
Lilling G, Nordenberg J, Rotter V, Goldfinger N, Peller S, Sidi Y. Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells. Cancer Investigation. 2002;20(4):509-517.
Offer H, Erez N, Zurer I, Tang X, Milyavsky M, Goldfinger N, Rotter V. The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis. 2002 Jun;23(6):1025-1032.
Shakked Z, Yavnilovitch M, Kalb Gilboa AJ, Kessler N, Wolkowicz R, Rotter V, Haran TE. DNA binding and 3'-5' exonuclease activity in the murine alternatively-spliced p53 protein. Oncogene. 2002 Aug 1;21(33):5117-5126.
Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, Rotter V. Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Research. 2003 Dec 15;63(24):8777-8783.
Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, Harris CC. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. The Journal of Clinical Investigation. 2003 Dec;112(12):1887-1894.
Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, Harris CC. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proceedings of the NationalAcademy of Sciences of the United States of America. 2003 Jan 7;100(1):143-148.
Milyavsky M, Shats I, Erez N, Tang X, Senderovich S, Meerson A, Tabach Y, Goldfinger N, Ginsberg D, Harris CC, Rotter V. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Research. 2003 Nov 1;63(21):7147-7157.
Peller S, Frenkel J, Lapidot T, Kahn J, Rahimi-Levene N, Yona R, Nissim L, Goldfinger N, Sherman DJ, Rotter V. The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts. Oncogene. 2003 Jul 24;22(30):4648-4655.
Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Human Mutation (Review). 2003 Mar;21(3):277-284.
Shats I, Milyavsky M, Erez N, Rotter V. The murine telomerase catalytic subunit shares the PAb-240 mutant specific epitope of the p53 protein. FEBS Letters. 2003 Jul 10;546(2-3):321-324.
Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene. 2003 Aug 28;22(36):5667-5676.
Erez N, Stambolsky P, Shats I, Milyavsky M, Kachko T, Rotter V. Hypoxia-dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene promoter. FEBS Letters. 2004 Jun 4;567(2-3):311-315.
Herkel J, Kam N, Erez N, Mimran A, Heifetz A, Eisenstein M, Rotter V, Cohen IR. Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: anti-idiotypes to the anti-p53 antibody are anti-DNA. European Journal of Immunology. 2004 Dec;34(12):3623-3632.
Matas D, Milyavsky M, Shats I, Nissim L, Goldfinger N, Rotter V. p53 is a regulator of macrophage differentiation. Cell Death and Differentiation. 2004 Apr;11(4):458-467.
Meerson A, Milyavsky M, Rotter V. p53 mediates density-dependent growth arrest. FEBS Letters. 2004 Feb 13;559(1-3):152-158.
Mimran A, Mor F, Carmi P, Quintana FJ, Rotter V, Cohen IR. DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response. The Journal of Clinical Investigation. 2004 Mar;113(6):924-932.
Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V. p53-dependent down-regulation of telomerase is mediated by p21waf1. The Journal of Biological Chemistry. 2004 Dec 3;279(49):50976-50985.
Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 2004 Jul 29;23(34):5759-5769.
Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Research. 2004 Nov 15;64(22):8318-8327.
Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V. The role of p53 in base excision repair following genotoxic stress. Carcinogenesis. 2004 Jan;25(1):11-19.
Milyavsky M, Tabach Y, Shats I, Erez N, Cohen Y, Tang X, Kalis M, Kogan I, Buganim Y, Goldfinger N, Ginsberg D, Harris CC, Domany E, Rotter V. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Research. 2005 Jun 1;65(11):4530-4543.
Orgad S, Goldfinger N, Cohen G, Rotter V, Solomon B. Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein. FEBS Letters. 2005 Oct 24;579(25):5609-5615.
Tabach Y, Milyavsky M, Shats I, Brosh R, Zuk O, Yitzhaky A, Mantovani R, Domany E, Rotter V, Pilpel Y. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Molecular Systems Biology. 2005;1:2005 0022.

Back to the Top

2006 - 2010

Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, Kalis M, Goldfinger N, Rotter V. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Research. 2006 Nov 15;66(22):10750-10759.
Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, Klocker H, Wasylyk B, Voller M, Aalders T, Schalken JA, Oren M, Rotter V. hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Research. 2006 Apr 1;66(7):3531-3540.
Rotter V. Spotlight on...Varda Rotter. Interview by Tine Walma. FEBS Letters. 2006 Sep 4;580(20):4763.
Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M, Rotter V. Regulation of AIF expression by p53. Cell Death and Differentiation. 2006 Dec;13(12):2140-2149.
Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene. 2006 Jan 19;25(3):359-369.
Efrati S, Berman S, Goldfinger N, Erez N, Averbukh Z, Golik A, Rotter V, Weissgarten J. Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension. Journal of Hypertension. 2007 May;25(5):1041-1052.
Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, Weisz L, Kogan I, Cohen M, Shatz M, Madar S, Kalo E, Goldfinger N, Yuan J, Ron S, MacKenzie K, Eden A, Rotter V. Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer cell. 2007 Feb;11(2):133-146.
Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG, Rotter V, Blandino G, Oren M. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Research. 2007 Mar 15;67(6):2396-2401.
Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene. 2007 Apr 2;26(15):2202-2211.
Shats I, Milyavsky M, Cholostoy A., Brosh R., Rotter V. Myocardin in tumor suppression and myofibroblast differentiation. Cell Cycle. 6: 1141-1146.
Tang X, Milyavsky M., Goldfinger N., Rotter V. Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress. Oncogene. 2007 May 28; [Epub ahead of print]
Tabach, Y., Brosh, R., Buganim, Y., Reiner A., Zuk, O., Yitzhaky, A., Koudritsky, M., Rotter, V., Domany, E. Wide-Scale Analysis of Human Functional Transcription Factor Binding Reveals a Strong Bias towards the Transcription Start Site. PlosONE. 2007 Aug 29;2(8):e80.
Kalo, E., Buganim, J., Shapira, K.E., Besserglick, H., Goldfinger, N., Weise, L., Stambolsky, P., Henis, Y.I., and V. Rotter. Mutant p53 attenuates the SMAD-dependent TGF-β1 signaling pathway by repressing the expression of type II TGF-β receptor. Mol. Cell Biol., 2007 27, 8228-8242.
Bossi, G., Marampon, F., Maor-Aloni, R., Zani, B, Rotter, V., Oren, M. Strano, S., Blandino, G., and Sacchi, A. Conditional RNA Interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 2008 7, 1870-1879.
Brosh, R., Shalgi, R., Liran, A., Landan, G., Korotayev, K., Nguyen, G., Enerly, E., Johnsen, H., Buganim, Y., Solomon, H., Goldstein, I., Madar, S., Goldfinger, Børresen-Dale, A-L, Ginsberg, D., Harris, C.C., Pilpel, Y., Oren, M., and Rotter, V. p53-repressed miRNAs are involved with E2F in a feed forward loop promoting proliferation. Mol. Sys. Biol. 2008 4:229. Epub 2008 Nov 25. Comment in: Mol. Syst. Biol. 2008;4:231.
Ke X.S., Qu Y., Goldfinger N., Rostad, K., Hovland R., Akslen, L.A., Rotter V., Øyan A.M., and Kalland K.H. Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One. 2008;3(10):e3368. Epub 2008 Oct 13.
Salah Z, Haupt S, Maoz M, Baraz L, Rotter V, 3, Peretz T, Haupt Y, and Bar-Shavit R. p53 controls hPar1 function and expression. Oncogene 2008 27, 6866-74. Epub 2008 Sep 29.
Marrazzo, E., Marchini, S., Tavecchio, M., Alberio, T., Previdi, S., Erba, E., Rotter V. and Broggini M. The expression of the ΔNp73β isoform of p73 leads to tetraploidy. European Journal Of Cancer 2008 45(3):443-53.
Molchadsky A., Shats I., Goldfinger N., Pevsner-Fischer M., Olson M, Rinon A., Tzahor E., Lozano G., Zipori D, Sarig R., Rotter V. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS ONE. 2008;3(11):e3707. Epub 2008 Nov 12.
Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J., Frolow F., Liran A., Rotter V., Shakked Z. Structural Basis of Restoring Sequence-Specific DNA Binding and Transactivation to Mutant p53 by Suppressor Mutations. J Mol Biol. 2009 9;385(1):249-265. Epub 2008 Oct 30.
Ke XS, Qu Y, Rostad K, Li WC, Lin B, Halvorsen OJ, Haukaas SA, Jonassen I, Petersen K, Goldfinger N, Rotter V, Akslen LA, Oyan AM, Kalland KH. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS ONE 2009 4(3):e4687. Epub 2009 Mar 5.
Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, Solomon H, Kogan I, Goldfinger N, Klocker H, Rotter V. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis 2009 30(1):20-7. Epub 2008 Oct 8.
Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, Brosh R, Buganim Y, Goldfinger N, Klocker H, Schalken JA, Rotter V. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis 2009 30(4):698-705. Epub 2009 Feb 20.
Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, Simansky D, Perlman M, Papa M, Yosepovich A, Rechavi G, Rotter V, Oren M . Cancer cells suppress p53 in adjacent fibroblasts. Oncogene 2009 12;28(6):933-6. Epub 2008 Dec 8.
Peller S, Tabach Y, Rotschild M, Garach-Joshua O, Cohen Y, Goldfinger N, Rotter V. Identification of gene networks associated with erythroid differentiation. Blood Cells Mol. Dis. 2009. 43, 74-80. Epub 2009 Mar 28.
Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 2009 Aug 20. Epub 2009 Aug 20.
Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N, Rotter V. Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Mol. Cancer Res. 2009 7(8):1212-23. Epub 2009 Aug 11.
Madar S, Goldstein I, Rotter V. Did experimental biology die? Lessons from 30 years of p53 research. Cancer Res. 2009 15;69(16):6378-6380. Epub 2009 Aug 4.
Zemach A, Paul LK, Stambolsky P, Efroni I, Rotter V, Grafi G. The C-terminal domain of the Arabidopsis AtMBD7 protein confers strong chromatin binding activity. Exp Cell Res. 2009 Aug 6. [Epub ahead of print]
Daniel-Carmi V, Makovitzki-Avraham E, Reuven EM, Goldstein I, Zilkha N, Rotter V, Tzehoval E, Eisenbach L. The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene. Int. J. Cancer 2009 Jun 19. [Epub ahead of print]
Shalgi R, Brosh R, Oren M, Pilpel Y, Rotter V. Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate. Aging (Albany NY)2009 Sep 8;1(9):762-770.
Yuan J, Yang BM, Zhong ZH, Shats I, Milyavsky M, Rotter V, Lock RB, Reddel RR, MacKenzie KL. Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase. Oncogene 2009 23;28(29):2678-89. Epub 2009 Jun 1.
Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, Oren M. Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene 2009 Oct 26. [Epub ahead of print]
Goldstein I, Rotter V. Mutations in the tetramerization domain of p53: more than just keeping monomers apart. Cell Cycle 2009 Oct 15;8(20):3259-60. Epub 2009 Oct 15.
Buganim Y, Rotter V. p53: balancing tumour suppression and implications for the clinic. Eur J Cancer 2009 Sep;45 Suppl 1:217-234.
Marrazzo E, Marchini S, Tavecchio M, Alberio T, Previdi S, Erba E, Rotter V, Broggini M. The expression of the DeltaNp73beta isoform of p73 leads to tetraploidy. Eur. J Cancer 2009;Feb;45(3):443-53. Epub 2008 Nov 12.
Brosh R, Rotter V. Transcriptional control of the proliferation cluster by the tumor suppressor p53. Mol. BioSyst. 2010 (6):17-29.
Oren M, Rotter V. Mutant p53 Gain-of-Function in Cancer. Cold Spring Harb Perspect Biol. 2010; Feb;2(2):a001107.
Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Sigfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 2010 Mar 16;17(3):273-285.
Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z, Rotter V. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS One. 2010 Mar 11;5(3):e9657.

Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M, Madar S, Goldstein I, Kalo E, Adam N, Gordin M, Rivlin N, Kogan I, Brosh R, Sefadia-Elad G, Goldfinger N, Sidransky D, Kloog Y, Rotter V. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res. 2010 Mar 15;70(6):2274-84. Epub 2010 Mar 2.

Brosh R, Sarig R, Natan EB, Molchadsky A, Madar S, Bornstein C, Buganim Y, Shapira T, Goldfinger N, Paus R, Rotter V. p53-dependent transcriptional regulation of EDA2R and its involvement in chemotherapy-induced hair loss. FEBS Lett. Jun 3;584(11):2473-2477. Epub 2010 Apr 29.

Solomon H, Brosh R, Buganim Y, Rotter V. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. Discov Med. 2010 May;9(48):448-454.

Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 2010 May 26. [Epub ahead of print]

Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O, Rotter V. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med. 2010 Aug 9. [Epub ahead of print]

Ke XS, Qu Y, Cheng Y, Li WC, Rotter V, Oyan AM, Kalland KH. Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomics. 2010 Nov 25;11(1):669.

Back to the Top

2011 - 2015

Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2011 Jan;18(1):2-11. Review.

Ke XS, Li WC, Hovland R, Qu Y, Liu RH, McCormack E, Thorsen F, Olsen JR, Molven A, Kogan-Sakin I, Rotter V, Akslen LA, Oyan AM, Kalland KH. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Exp Cell Res. 2011 Jan 15;317(2):234-247.

Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, Domany E. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One. 2011 Jan 31; 6(1):e14632. [Epub 2011 Jan 31]

Dell'orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M, Strano S, Rotter V, Oren M, Blandino G. ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters. OMICS. 2011 Feb 19, 15:5:305-312..

Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V. Mutant p53^R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ. 2011 Feb;18(2):271-81.

Madar S, Stambolsky P, Rotter V. Unleash the wild type: Restoration of p53 suppressive activity in skin cancer. Cell Cycle. 2011 Mar 1;10 (5). [Epub ahead of print]

Kravchenko-Balasha N, Remacle F, Gross A, Rotter V, Levitzki A, Levine RD. Convergence of logic of cellular regulation in different premalignant cells by an information theoretic approach. BMC Syst Biol. 2011 Mar 16; 5:42. [Epub 2011 Mar 16]

Bornstein C, Brosh R, Molchadsky A, Madar S, Kogan-Sakin I, Goldstein I, Chakravarti D, Flores ER, Goldfinger N, Sarig R, Rotter V. SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. Mol Cell Biol. 2011 Apr;31(8):1679-89. [Epub 2011 Feb 7]

Sarig R, Rotter V. Can an iPS cell secure its genomic fidelity? Cell Death Differ. 2011 May;18(5):743-4. No abstract available.

Rinon A, Molchadsky A, Nathan E, Yovel G, Rotter V, Sarig R, Tzahor E. p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. Development. 2011 May;138(9):1827-38. [Epub 2011 Mar 29]

Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011 Apr;2(4):466-74.

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R. TMPRSS2/ERG Promotes Epithelial to Mesenchymal Transition through the ZEB1/ZEB2 Axis in a Prostate Cancer Model. PLoS One. 2011 2011;6(7):e21650.

Madar S, Solomon H, Rotter V. Same stem cells but different: Isogenic embryonic stem cells harboring different p53 mutants. Cell Cycle. 2011 Jul 15;10(14). [Epub ahead of print].

Buganim Y, Madar S, Rais Y, Pomeraniec L, Harel E, Solomon H, Kalo E, Goldstein I, Brosh R, Haimov O, Avivi C, Polak-Charcon S, Goldfinger N, Barshack I, Rotter V. Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression. Carcinogenesis. 2011 Sep 7. [Epub ahead of print]

Madar S, Goldstein I, Neeman O, Rotter V. Beyond tumor suppression: p53 controls blastocyst implantation. Cell Cycle. 2011 Dec 15;10(24):4203.

Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death Differ.. 2012 Jan;19(1):180-83..

Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, Rotter V. p53, a novel regulator of lipid metabolism pathways. J Hepatol.. 2012 March 56:3:656-62.

Solomon H, Buganim Y, Pomeraniec L, Beatus T, Assia Y, Kogan-Sakin I, Madar S, Goldstein I, Brosh R, Kalo E, Goldfinger N, Rotter V. Various p53 mutant types differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci. 2012 Mar 16. [Epub ahead of print]

Kravchenko-Balasha N, Levitzki A, Goldstein A, Rotter V, Gross A, Remacle F, Levine RD. On a fundamental structure of gene networks in living cells. Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4702-7.

Goldstein I, Madar S, Rotter V. Cancer research, a field on the verge of a paradigm shift? Trends Mol Med. 2012 June 18:(6): 299-303.

Goldstein I, Rotter V. Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends Endocrinol. Metab. 2012 Nov;23(11):567-75.

Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, Goldstein I, Madar S, Rotter V. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high ROS levels. J Cell Sci. 2012 Nov 15;125(Pt 22):5578-86.

Heidegger I, Ofer P, Doppler W, Rotter V, Klocker H, Massoner P. Diverse Functions of IGF/Insulin Signaling in Malignant and Noncancerous Prostate Cells: Proliferation in Cancer Cells and Differentiation in Noncancerous Cells. Endocrinology 2012 Oct;153(10):4633-43.

Landan G, Cohen NM, Mukamel Z, Bar A, Molchadsky A, Brosh R, Horn-Saban S, Zalcenstein DA, Goldfinger N, Zundelevich A, Gal-Yam EN, Rotter V, Tanay A. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat. Genet. 2012 Oct 14;44(11):1207-14.

Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, Rotter V. Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis 2013 Jan;34(1):190-8..

Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y, Rivlin N, Goldfinger N, Folgiero V, Falcioni R, Sarig R, Rotter V. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ. 2013 Feb 15. doi: 10.1038/cdd.2013.9. [Epub ahead of print]
Brosh R, Assia-Alroy Y, Molchadsky A, Bornstein C, Dekel E, Madar S, Shetzer Y, Rivlin N, Goldfinger N, Sarig R, Rotter V. p53 Counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death Differ.2013 Feb;20(2):312-20.

Back to the Top